Graft Polymer (UK) PLC ( (GB:GPL) ) just unveiled an update.
Graft Polymer has announced a rebranding to Solvonis Therapeutics plc, with the name change reflecting its focus on developing novel therapeutics for mental health and substance use disorders. This rebranding includes a new website and branding strategy, aligning with the company’s mission to provide innovative therapeutic solutions. The name change, effective from 15 January 2025 on the London Stock Exchange, requires no immediate action from shareholders, as existing share certificates remain valid. This move represents Solvonis Therapeutics’ commitment to empowering patients through improved treatments for mental health and addiction conditions.
More about Graft Polymer (UK) PLC
Graft Polymer, now known as Solvonis Therapeutics plc, is an innovative biotechnology company specializing in the development of intellectual property and co-development of therapeutics for mental health and substance use disorders. The company aims to improve outcomes for individuals with these conditions, particularly focusing on trauma-related mental health issues such as PTSD, which affects millions across the U.S., UK, and EU.
YTD Price Performance: -14.63%
Average Trading Volume: 24,696,755
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £4.02M
For an in-depth examination of GPL stock, go to TipRanks’ Stock Analysis page.